Comparison of N-Terminal Pro-Brain Natriuretic Peptide Versus Electrophysiologic Study for Predicting Future Outcomes in Patients With an Implantable Cardioverter Defibrillator After Myocardial Infarction

American Journal of Cardiology

Volumn 100, Issue 4, 2007, Pages 635-639

  Yu, Hong ^a   Oswald, Hanno ^a   Gardiwal, Ajmal ^a   Lissel, Christoph ^a   Klein, Gunnar ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEFIBRILLATOR; ELECTROPHYSIOLOGY; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ARRHYTHMIA; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; RISK FACTORS; SURVIVAL RATE;

EID: 34547687773     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.03.074     Document Type: Article

References (30)

1. Berger R., Huelsman M., Strecker K., Bojic A., Moser P., Stanek B., and Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
2. Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
3. Verma A., Kilicaslan F., Martin D.O., Minor S., Starling R., Marrouche N.F., Almahammed S., Wazni O.M., Duggal S., Zuzek R., et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 92 (2006) 190-195
4. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., Jones R.H., Kereiakes D., Kupersmith J., Levin T.N., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40 (2002) 1366-1374
5. Korte T., Jung W., Ostermann G., Wolpert C., Spehl S., Esmailzadeh B., and Luderitz B. Hospital readmission after transvenous cardioverter/defibrillator implantation; a single centre study. Eur Heart J 21 (2000) 1186-1191
6. Richards D.A., Byth K., Ross D.L., and Uther J.B. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction?. Circulation 83 (1991) 756-763
7. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Levine J.H., Saksena S., Waldo A.L., Wilber D., Brown M.W., and Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 (1996) 1933-1940
8. Buxton A.E., Lee K.L., DiCarlo L., Gold M.R., Greer G.S., Prystowsky E.N., O'Toole M.F., Tang A., Fisher J.D., Coromilas J., Talajic M., and Hafley G. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 342 (2000) 1937-1945
9. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
10. Marin-Grez M., Fleming J.T., and Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324 (1986) 473-476
11. Richards A.M., McDonald D., Fitzpatrick M.A., Nicholls M.G., Espiner E.A., Ikram H., Jans S., Grant S., and Yandle T. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J Clin Endocrinol Metab 67 (1988) 1134-1139
12. Tonolo G., Richards A.M., Manunta P., Troffa C., Pazzola A., Madeddu P., Towrie A., Fraser R., and Glorioso N. Low-dose infusion of atrial natriuretic factor in mild essential hypertension. Circulation 80 (1989) 893-902
13. Floras J.S. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 81 (1990) 1860-1873
14. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., Hastings J., and Esler M.D. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37 (2001) 1221-1227
15. Atarashi K., Mulrow P.J., and Franco-Saenz R. Effect of atrial peptides on aldosterone production. J Clin Invest 76 (1985) 1807-1811
16. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., and Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
17. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
18. Whang W., Mittleman M.A., Rich D.Q., Wang P.J., Ruskin J.N., Tofler G.H., Muller J.E., and Albert C.M. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation 109 (2004) 1386-1391
19. Hansen D.E., Craig C.S., and Hondeghem L.M. Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback. Circulation 81 (1990) 1094-1105
20. Franz M.R., Cima R., Wang D., Profitt D., and Kurz R. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 86 (1992) 968-978
21. Reiter M.J. Effects of mechano-electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Cardiovasc Res 32 (1996) 44-51
22. Isnard R., Pousset F., Chafirovskaia O., Carayon A., Hulot J.S., Thomas D., and Komajda M. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 146 (2003) 729-735
23. Page R.L. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Am J Cardiol 85 (2000) 1481-1485
24. Steinberg J.S., Martins J., Sadanandan S., Goldner B., Menchavez E., Domanski M., Russo A., Tullo N., and Hallstrom A. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 142 (2001) 520-529
25. Dorian P., Borggrefe M., Al-Khalidi H.R., Hohnloser S.H., Brum J.M., Tatla D.S., Brachmann J., Myerburg R.J., Cannom D.S., van der Laan M., et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110 (2004) 3646-3654
26. Aiba T., Kurita T., Taguchi A., Shimizu W., Suyama K., Aihara N., and Kamakura S. Long-term efficacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circ J 66 (2002) 367-371
27. Wathen M.S., DeGroot P.J., Sweeney M.O., Stark A.J., Otterness M.F., Adkisson W.O., Canby R.C., Khalighi K., Machado C., Rubenstein D.S., and Volosin K.J. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 110 (2004) 2591-2596
28. Constantini O. The Alternans Before Cardioverter Defibrillator (ABCD) trial: a non-invasive strategy for primary prevention of sudden cardiac death using T-wave alternans. Program and abstracts from the American Heart Association 2006 Scientific Sessions; November 12-15 (2006) Chicago, Ill.
29. Connolly S.J., Gent M., Roberts R.S., Dorian P., Roy D., Sheldon R.S., Mitchell L.B., Green M.S., Klein G.J., and O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 (2000) 1297-1302
30. Klein R.C., Raitt M.H., Wilkoff B.L., Beckman K.J., Coromilas J., Wyse D.G., Friedman P.L., Martins J.B., Epstein A.E., Hallstrom A.P., et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 14 (2003) 940-948